# Adrian Thomas

> Medico australiano, VP Global Public Health di Johnson & Johnson, architetto della risposta pharma alle minacce pandemiche

## Dati Essenziali

| Aspetto | Dettaglio |
|---------|-----------|
| **Nazionalita'** | Australiana |
| **Campo** | Medicina, farmacologia clinica, global public health |
| **Titoli** | MD, FRACP |
| **Residenza** | USA |

---

## Formazione

| Periodo | Istituzione | Dettaglio |
|---------|-------------|-----------|
| **-** | [University of Melbourne](../universities/university-melbourne.md) | MBBS (Bachelor of Medicine, Bachelor of Surgery) |
| **-** | Royal Australasian College of Physicians | FRACP (Fellow) |

**Specializzazioni:**
- Clinical pharmacology
- Vascular medicine
- Medical administration (Fellow, College of Medical Administrators)

---

## Carriera e Ruoli

### Timeline Professionale

| Periodo | Ruolo | Organizzazione |
|---------|-------|----------------|
| **-** | Clinical Research Physician | [Eli Lilly](../pharma/eli-lilly.md) |
| **-** | Associate Director Clinical Research | Eli Lilly ANZ |
| **-** | Director Medical Affairs, Australasia | [Schering-Plough](../pharma/schering-plough.md) |
| **2013-oggi** | VP Global Public Health | [Johnson & Johnson](../pharma/johnson-johnson.md) (Janssen) |

### Focus Programmatico a J&J

| Area | Dettaglio |
|------|-----------|
| **Tuberculosis** | Accesso a trattamenti MDR-TB |
| **AMR** | Antimicrobial Resistance mitigation |
| **Pandemic Preparedness** | Global Health Security |
| **USAID Partnership** | MoU dal 2016 su MDR-TB e AMR |

---

## Rete di Connessioni

### Mappa delle Appartenenze

```
                      ADRIAN THOMAS
                            |
       +----------+---------+---------+----------+
       |          |         |         |          |
       v          v         v         v          v
   Melbourne   Eli Lilly  Schering  J&J/Janssen Event 201
   (MBBS)      (research)  Plough   (2013-)    (player)
                           (med affairs)
```

### Industria Farmaceutica

| Organizzazione | Ruolo | Focus |
|----------------|-------|-------|
| [Johnson & Johnson](../pharma/johnson-johnson.md) | VP Global Public Health | Pandemic preparedness, TB, AMR |
| [Eli Lilly](../pharma/eli-lilly.md) | Associate Director | Clinical Research |
| [Schering-Plough](../pharma/schering-plough.md) | Director | Medical Affairs |

### Network Event 201

| Connessione | Dettaglio |
|-------------|-----------|
| [Johns Hopkins Center](../think-tanks/jh-health-security.md) | Partecipante simulazione |
| [Gates Foundation](../foundations/gates-foundation.md) | Co-organizzatore evento |
| [WEF](../forums/wef.md) | Co-organizzatore evento |

---

## Potere Esercitato

### Global Public Health - Johnson & Johnson

| Aspetto | Dettaglio |
|---------|-----------|
| **Ruolo** | VP con responsabilita' su programmi, strategie e policy globali |
| **Focus** | Malattie infettive, TB multi-resistente, AMR, Ebola, Dengue, HIV |
| **Partnership** | USAID (MoU 2016 esteso), governi, ONG |

### Event 201

Partecipo' come player a [Event 201](../events/2019-event-201.md) (18 ottobre 2019), rappresentando il settore farmaceutico nell'esercitazione pandemica. Il suo ruolo a J&J in pandemic preparedness lo rendeva un partecipante naturale per discutere:
- Produzione e distribuzione vaccini
- Medical countermeasures
- Collaborazione pubblico-privato

Due mesi dopo apparve SARS-CoV-2. J&J sviluppo' poi uno dei vaccini COVID-19 approvati.

---

## Citazioni Significative

> "Global health security requires unprecedented collaboration between governments, industry, and international organizations."
> â€” Adrian Thomas, su pandemic preparedness

---

## Connessioni PowerLink

### Eventi

| Evento | Ruolo |
|--------|-------|
| [Event 201](../events/2019-event-201.md) | Player (ottobre 2019) |

### Organizzazioni

| Entita' | Connessione |
|---------|-------------|
| [Johnson & Johnson](../pharma/johnson-johnson.md) | VP Global Public Health (2013-) |
| [Eli Lilly](../pharma/eli-lilly.md) | Associate Director Clinical Research |
| [Schering-Plough](../pharma/schering-plough.md) | Director Medical Affairs |
| [University of Melbourne](../universities/university-melbourne.md) | Alumni (MBBS) |

---

## Timeline

| Anno | Evento |
|------|--------|
| **-** | MBBS, University of Melbourne |
| **-** | FRACP, Royal Australasian College of Physicians |
| **-** | Clinical Research, Eli Lilly |
| **-** | Medical Affairs Director, Schering-Plough |
| **2013** | Entra in Johnson & Johnson/Janssen |
| **2014** | VP Global Public Health |
| **2016** | MoU con USAID su MDR-TB |
| **2019** | Partecipa a Event 201 |

---

## Domande Aperte

- [ ] Anno di nascita
- [ ] Periodi esatti a Eli Lilly e Schering-Plough
- [ ] Ruolo specifico nello sviluppo vaccino COVID-19 J&J

---

## Fonti

### Biografie
- [Johns Hopkins - Event 201 Player Bio](https://www.centerforhealthsecurity.org/event201/players/thomas.html)
- [Aspen Ideas - Adrian Thomas](https://www.aspenideas.org/speakers/adrian-thomas)
- [H20 Summit - Adrian Thomas Bio](https://h20annualsummit.com/portfolio-item/adrian-thomas-vice-president-global-public-health-johnson-johnson/)

### Istituzioni
- [Johnson & Johnson - Global Public Health](https://www.jnj.com/gph/call-to-protect-public-health-by-bolstering-the-worlds-defense-against-antimicrobial-resistance)
- [CSIS - Intersecting Pandemics](https://www.csis.org/analysis/intersecting-pandemics-adrian-thomas-jj-tuberculosis-tb-covid-19)

---

*Ultimo aggiornamento: Febbraio 2026*
